Adjuvant treatment of ovarian carcinoma with tranexamic acid.
作者信息
Astedt B
出版信息
J Clin Pathol Suppl (R Coll Pathol). 1980;14:74-6.
Abstract
摘要
相似文献
1
Adjuvant treatment of ovarian carcinoma with tranexamic acid.氨甲环酸辅助治疗卵巢癌
J Clin Pathol Suppl (R Coll Pathol). 1980;14:74-6.
2
[Treatment of advanced cancer with Cyclocapron (tranexamic acid)].用氨甲环酸治疗晚期癌症
Lakartidningen. 1977 Aug 10;74(32):2679-80.
3
Arrest of growth of ovarian tumor by tranexamic acid.氨甲环酸对卵巢肿瘤生长的抑制作用。
JAMA. 1977 Jul 11;238(2):154-5. doi: 10.1001/jama.238.2.154.
4
Tranexamic acid for the treatment of advanced ovarian carcinoma.氨甲环酸用于治疗晚期卵巢癌。
Acta Obstet Gynecol Scand. 1983;62(3):265-6. doi: 10.3109/00016348309155805.
5
Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid).用纤维蛋白溶解抑制剂（氨甲环酸）治疗晚期卵巢癌。
Acta Obstet Gynecol Scand. 1980;59(3):285-7. doi: 10.3109/00016348009155415.
6
[Cyklokapron (tranexamic acid) in the treatment of patients with advanced neoplasms].[氨甲环酸（止血环酸）用于晚期肿瘤患者的治疗]
Tidsskr Nor Laegeforen. 1978 Oct 10;98(28):1368-70.
7
[Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy].孕期使用氨甲环酸（凝血酸）的长期治疗
Ugeskr Laeger. 1976 Jul 12;138(29):1781-2.
8
[Neonatal antihemorrhagic treatment with tranexamic acid].[氨甲环酸用于新生儿抗出血治疗]
Minerva Pediatr. 1976 Feb 25;28(6):345.
9
[Cyklokapron in the treatment of neoplasms].[氨甲环酸在肿瘤治疗中的应用]
Tidsskr Nor Laegeforen. 1978 Oct 10;98(28):1360-1.
10
[Treatment of hypermenorrhea with tranexamic acid].氨甲环酸治疗月经过多
Ugeskr Laeger. 1983 Sep 5;145(36):2759-60.
引用本文的文献
1
Clinical trials with anticoagulant and antiplatelet therapies.
Cancer Metastasis Rev. 1992 Nov;11(3-4):421-31. doi: 10.1007/BF01307191.
本文引用的文献
1
The Application of Soybean Inhibitor in Tissue Cultivation.大豆抑制剂在组织培养中的应用
Science. 1949 Jun 17;109(2842):611-2. doi: 10.1126/science.109.2842.611.
2
On the use of fibrinolysin inhibitors in plasma clot tissue culture.关于纤维蛋白溶酶抑制剂在血浆凝块组织培养中的应用
Exp Cell Res. 1960 Oct;21:232-5. doi: 10.1016/0014-4827(60)90371-2.
3
Purification and characterization of a cellular fibrinolytic factor associated with oncogenic transformation: the plasminogen activator from SV-40-transformed hamster cells.与致癌转化相关的细胞纤溶因子的纯化与特性鉴定：来自SV - 40转化仓鼠细胞的纤溶酶原激活物
Biochim Biophys Acta. 1974 Mar 27;340(3):339-47. doi: 10.1016/0005-2787(74)90279-2.
4
Properties of plasminogen activators formed by neoplastic human cell cultures.人肿瘤细胞培养物形成的纤溶酶原激活剂的特性
J Exp Med. 1974 May 1;139(5):1317-28. doi: 10.1084/jem.139.5.1317.
5
Release of fibrinolytic activators from human ovarian tumours in organ culture.
Ann Chir Gynaecol. 1976;65(6):405-7.
6
Purification of urokinase by affinity chromatography.通过亲和色谱法纯化尿激酶。
Biochim Biophys Acta. 1976 Aug 12;445(1):215-22. doi: 10.1016/0005-2744(76)90174-1.
7
Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis.用化疗药物治疗晚期乳腺癌并抑制凝血和纤维蛋白溶解。
Acta Med Scand. 1977;201(5):491-3. doi: 10.1111/j.0954-6820.1977.tb15735.x.
8
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.组织培养中释放的尿激酶与卵巢癌纤溶酶原激活物的免疫学特性
Nature. 1976 Jun 17;261(5561):595-7. doi: 10.1038/261595a0.
9
Arrest of growth of ovarian tumor by tranexamic acid.氨甲环酸对卵巢肿瘤生长的抑制作用。
JAMA. 1977 Jul 11;238(2):154-5. doi: 10.1001/jama.238.2.154.
10
Antineoplastic-drug effect evaluated with a new X-ray stereophotographic measurement of the tumour volume.采用一种新的X射线立体摄影测量肿瘤体积的方法评估抗肿瘤药物效果。
Ann Chir Gynaecol. 1978;67(2):82-4.
Zotero 插件